May C, Landers SM, Bolshakov S, Ma X, Ingram DR, Kivlin CM, Watson KL, Al-Sannaa G, Bhalla AD, Wang W, Lazar AJ, Torres KE. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther. 2017;18(10), 747–826. doi:10.1080/15384047.2017.1373230
When the article was first published online, Acknowledgments and Funding section were incorrectly mentioned in the paper.
This should have been as below:
Financial support
We gratefully acknowledge the support of NIH/NCI K08CA160443 (to KET), the Sally M. Kingsbury Sarcoma Research Foundation (supporting CDM), the Jay Vernon Jackson Fund (supporting SML and XM), Michael and Mary Kay Poulos (supporting KLW), Friends of Sarcoma Fund (to KET), the Johnnie M Lowe Sarcoma Research Endowment (to KET) and the Ferrin Randall Zeitlin Foundation for Sarcoma Research (to KET). None of the funding organizations had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
The authors apologize for these errors.
Acknowledgments
We gratefully acknowledge the support of the National Institutes of Health/National Cancer Institute (NIH/NCI Cancer Center Support Grant P30CA016672) and use of the Flow Cytometry and Cellular Imaging Facility. Short tandem repeat DNA fingerprinting was done by the Characterized Cell Line Core (also funded by NCI P30CA016672).